KL2 mentored career development programs at clinical and translational science award hubs: Practices and outcomes
KL2 mentored career development programs at clinical and translational science award hubs: Practices and outcomes
复制标题
DOI：
10.1017/cts.2019.424
复制
发表时间：
2020-02-01
影响因子：
2.6
通讯作者：
Umans, Jason G.
中科院分区：
文献类型：
--
作者：
Sorkness, Christine A.;Scholl, Linda;Umans, Jason G.
简介：NIH临床和转化科学奖（CTSA）包括KL 2指导的职业发展奖，用于开始临床和转化研究的教师。对KL 2领导人的调查揭示了计划实践，课程元素和有关学者特征和成果的令人信服的数据。方法：我们进行了文献综述，制定了调查结构，并从整个CTSA联盟获得了输入。2016年秋季，一份REDCap调查通过电子邮件发送给了61个活跃的项目。结果：55个项目（90.2%）作出了回应。答卷者获得的供资时间从3年到11年不等，其中包括22个“成熟”中心获得的供资时间>= 8年。计划队列规模为56%“小型”，22%“中型”和22%“大型”。“中心提供与临床和转化研究相关的广泛的能力培训机会，包括研究生学位，导师和赠款写作。72%的中心报告了并行的“相当于第二学段”的职业发展计划。所有中心分享其培训，并促进与其他早期阶段调查人员的交流。共有1，517名KL 2学者获得资助。KL 2获奖者在学科，研究项目和代表性方面各不相同; 54%是女性，12%自认为在生物医学研究中代表性不足。87%的学者有2-3个导师，目前支持2-3年。78%的校友留在CTSA机构的转化科学。在获得KL 2奖之后，NIH最常见的支持形式是个人职业发展奖。结论：KL 2是一个独特的职业发展奖，由能力调整的培训机会和跨学科导师塑造，为翻译研究途径提供信息。跟踪KL 2学者的传统和新颖成果对于捕捉他们的职业轨迹和对健康的影响至关重要。
Introduction: NIH Clinical and Translational Science Awards (CTSAs) include KL2 mentored career development awards for faculty commencing clinical and translational research. A survey of KL2 leaders revealed program practices, curricular elements and compelling data about scholar characteristics and outcomes. Methods: We conducted a literature review, framed the survey construct, and obtained input from across the CTSA consortium. A REDCap survey was emailed in fall 2016 to 61 active programs. Results: Fifty-five programs (90.2%) responded. Respondents had been funded from 3 to 11 years, including 22 "mature" hubs funded for >= 8 years. Program cohort sizes were 56% "small", 22% "medium", and 22% "large." Hubs offer extensive competency-aligned training opportunities relevant to clinical and translational research, including graduate degrees, mentorship, and grant-writing. Seventy-two percent of hubs report parallel "KL2-equivalent" career development programs. All hubs share their training and facilitate intermingling with other early stage investigators. A total of 1,517 KL2 scholars were funded. KL2 awardees are diverse in their disciplines, research projects, and representation; 54% are female and 12% self-identified as underrepresented in biomedical research. Eighty-seven percent of scholars have 2-3 mentors and are currently supported for 2-3 years. Seventy-eight percent of alumni remain at CTSA institutions in translational science. The most common form of NIH support following scholars' KL2 award is an individual career development award. Conclusions: The KL2 is a unique career development award, shaped by competency-aligned training opportunities and interdisciplinary mentorship that inform translational research pathways. Tracking both traditional and novel outcomes of KL2 scholars is essential to capture their career trajectories and impact on health.